Indivior (INDV) stock receives a new Overweight rating and a $46 target from Barclays due to business transformation and commercial execution. Read more here.
Indivior gains new Overweight at Barclays on business turnaround
Jun 18, 2026, 11:52 AM ETIndivior Pharmaceuticals, Inc. (INDV) StockBy : Dulan Lokuwithana, SA News Editor
Comments
Barclays initiated its coverage of Indivior Pharmaceuticals (INDV) wi… [386 chars]
Source: Seeking Alpha | Published: 2026-06-18T15:52:29Z
Credit: Seeking Alpha
